New research shows that the efficacy of the new crown vaccine in severely obese adults is significantly reduced

The following is the New research shows that the efficacy of the new crown vaccine in severely obese adults is significantly reduced recommended by recordtrend.com. And this article belongs to the classification: novel coronavirus.

New research shows that compared with normal weight people, the immune response of severely obese adults to covid-19 vaccination is significantly weakened. Pfizer /biontech has stronger antibody reaction with patients with severe obesity than coronavac.

New research shows that the immune response of severely obese adults (18 years old or older) to covid-19 vaccination is significantly weaker than that of normal weight people. The study was conducted by Professor Volkan Demirhan yumuk and his colleagues from Istanbul University, Turkey, and was presented at the European obesity Conference (ECO) held in Maastricht, the Netherlands this year (may 4-7).

The study also found that the severely obese people vaccinated with Pfizer / Biotechnology bnt162b2 mRNA vaccine (BMI more than 40kg/m2) produced significantly more antibodies than those vaccinated with coronavac (inactivated sars-cov-2), indicating that Pfizer / Biotechnology’s vaccine may be a better choice for this vulnerable population.

Obesity is a disease that complicates the course of covid-19. The antibody response of sars-cov-2 vaccine in obese adults may be affected. Vaccines against influenza, hepatitis B and rabies have shown reduced response in obese patients.

To learn more, the researchers investigated the antibody responses of 124 adults with severe obesity (mean age 42-63 years) who visited the obesity center of the Affiliated Hospital of the University of Istanbul Cerrahpasa Medical College from August to November 2021 after receiving Pfizer / Biotechnology and coronavac vaccines. They also recruited 166 normal weight adults as the control group (BMI less than 25kg/m2, mean age 39-47 years), who were treated in the vaccination Department of Cerrahpasa hospital.

The researchers measured antibody levels in blood samples collected from patients and normal weight controls who had received two doses of Pfizer / biotechnology or coronavac vaccine and a second dose four weeks ago. Participants were classified by history of infection as having previously had covid-19 or not (as confirmed by their antibody profiles).

In general, 130 participants received two doses of Pfizer / biological ntech vaccine, and 160 participants received two doses of coronavac vaccine, of which 70 participants had previously been infected with sars-cov-2 (see the table in the editor’s note).

Among those who had not previously been infected with sars-cov-2 and had received Pfizer /biontech vaccine, antibody levels in severely obese patients were more than three times lower than those in normal weight controls (mean 5823 vs 19371 au/ml).

Similarly, among participants who had not previously been infected with sars-cov-2 and had received coronavac vaccine, antibody levels in severely obese patients were 27 times lower than those in normal weight controls (mean 178 vs 4894 au/ml).

However, among those who had been infected with sars-cov-2, there was no significant difference in antibody levels between severely obese patients and those vaccinated with Pfizer / biotechnology or coronavac vaccine and normal weight controls (mean 39043 vs 14115 au/ml and 3221 vs 7060 au/ml, respectively).

Interestingly, the analysis found that in severely obese patients, whether they had sars-cov-2 infection or not, the antibody level of Pfizer /biontech vaccine users was significantly higher than that of coronavac vaccine users.

From cnbeta Com read more: ISDA: Delta variant of novel coronavirus raised the threshold of group immunity to 80%-90%. CDC in the United States: nearly 10% of patients with neocoronavirus were re admitted to the hospital within two months after discharge CDC in the United States: in early April 2022, the subtype Ba of Omicron virus 2. The related cases accounted for 86% of the new cases in the United States. Circulation research: the study found that the new coronavirus can infect pacemaker cells that maintain heart rhythm and trigger the process of self destruction. South Korea: 1887337 children under the age of 9 in South Korea were infected with novel coronavirus, accounting for half of the children at that age. Epidemiologist: it is estimated that the Omicron subtype ba 2. It will replace other variant strains of new atlas in the United States: the research predicts that the delay in diagnosis related to the new coronavirus pandemic will promote the increase in the number of cancer deaths. University of Pennsylvania: researchers found that the sequence of novel coronavirus in pet cats is almost the same as that in humans. Who: there have been 185 countries and regions infected with delta variant strains. CDC in the United States: 1533 cases of 7-day moving average deaths in the United States, a new high for half a year. Johns Hopkins University: more than 660000 new crown deaths in the United States Bloomberg News: more than 30% of Britons deleted the new crown tracking app. Proceedings of the National Academy of Sciences: the total weight of novel coronavirus, which has infected more than 170 million people worldwide, is between 0.22 and 22 pounds BTG: the survey shows that the COVID-19 has led to an increase in the attention of enterprises to e-waste. State Department: by the end of February 2022, the full vaccination rate of China’s new crown vaccine has exceeded 87%

If you want to get the full report, you can contact us by leaving us the comment. If you think the information here might be helpful to others, please actively share it. If you want others to see your attitude towards this report, please actively comment and discuss it. Please stay tuned to us, we will keep updating as much as possible to record future development trends.

RecordTrend.com is a website that focuses on future technologies, markets and user trends. We are responsible for collecting the latest research data, authority data, industry research and analysis reports. We are committed to becoming a data and report sharing platform for professionals and decision makers. We look forward to working with you to record the development trends of today’s economy, technology, industrial chain and business model.Welcome to follow, comment and bookmark us, and hope to share the future with you, and look forward to your success with our help.